Medulloblastoma and primitive neuroectodermal tumors

Handbook of Clinical Neurology

Volumn 105, Issue , 2012, Pages 529-548

  Packer, Roger J ^a   Macdonald, Tobey ^a   Vezina, Gilbert ^a   Keating, Robert ^a   Santi, Mariarita ^b  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84855565531     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-444-53502-3.00007-0     Document Type: Chapter

References (141)

1. Albright L., Reigel D. Management of hydrocephalus secondary to posterior fossa tumors. J Neurosurg 1977, 46:52-55.
2. Albright A.L., Wisoff J.H., Zeltzer P., et al. Prognostic factors in children with supratentorial (nonpineal) primitive neuroectodermal tumors. Pediatr Neurosurg 1995, 22:1-7.
3. Albright A.L., Wisoff J.H., Zeltzer P.M., et al. Effects of medulloblastoma resections on outcome in children: a report from the Children's Cancer Group. Neurosurgery 1996, 38:265-271.
4. Albright A.L., Sposto R., Holmes E., et al. Correlation of neurosurgical subspecialization with outcomes in children with malignant brain tumors. Neurosurgery 2000, 47:879-887.
5. Bailey C.C., Gnekow A., Wellek S., et al. Prospective randomized trial of chemotherapy given before radiotherapy in childhood medulloblastoma. International Society of Paediatric Oncology (SIOP) and the (German) Society of Paediatric Oncology (GPO): SIOP II. Med Pediatr Oncol 1995, 25:155-178.
6. Berger M.S., Baumeister B., Geyer J.R., et al. The risks of metastases from shunting in children with primary central nervous system tumors. J Neurosurg 1991, 74:872-877.
7. Bertolone S.J., Baum E.S., Krivit W., et al. A phase II study of cisplatin therapy in recurrent childhood brain tumors: a report from the Children's Cancer Group. J Neurooncol 1989, 7:5-11.
8. Blaney S.M., Boyett J., Friedman H.S., et al. Phase I clinical trial of mafosfamide in infants and children aged 3years of younger with newly diagnosed embryonal tumors: a Pediatric Brain Tumor Consortium Study (PBTC-001). J Clin Oncol 2005, 23:525-531.
9. Bowers D.C., Liu Y., Leisenring W., et al. Late-occurring stroke among long-term survivors of childhood leukemia and brain tumors: a report from the Childhood Cancer Survival Study. J Clin Oncol 2006, 24:5277-5282.
10. Brown H.G., Kepner J.L., Perlman E.J., et al. "Large cell/anaplastic" medulloblastomas: a Pediatric Oncology Group Study. J Neuropathol Exp Neurol 2000, 59:857-865.
11. Bunin G.R., Kuijten R.R., Buckley J.D., et al. Relation between maternal diet and subsequent primitive neuroectodermal brain tumors in young children. N Engl J Med 1993, 329:536-541.
12. Bunin G.R., Buckley J.D., Boessel C.P., et al. Risk factors for astrocytic glioma and primitive neuroectodermal tumor of the brain in young children: a report from the Children's Cancer Group. Cancer Epidemiol Biomarkers Prev 1994, 3:197-204.
13. Burger P.C., Scheithauer B.W. Tumors of the central nervous system. Atlas of Tumor Pathology, 3rd series, fascicle 10 1994, 259-286. Armed Forces Institute of Pathology, Washington, DC. J. Rosai, L.H. Sobin (Eds.).
14. Burger P.C., Grahmann F.C., Bliestle A., et al. Differentiation in the medulloblastoma. A histological and immunohistochemical study. Acta Neuropathol (Berl) 1987, 73:115-123.
15. Butler R.W., Copeland D.R. Attentional processes and their remediation in children treated for cancer: a literature review and the development of a therapeutic approach. J Int Neuropsychol Soc 2002, 8:115-124.
16. Chi S.N., Gardner S.L., Levy A.S., et al. Feasibility and response to induction chemotherapy intensified with high-dose methotrexate for young children with newly diagnosed high-risk disseminated medulloblastoma. J Clin Oncol 2004, 22:4881-4887.
17. Chicchi M.F., Smirniotopoulos J.G., Mena H. Pineal parenchymal tumors: CT and MR features. J Comput Assist Tomogr 1995, 19:509-517.
18. Coffin C.M., Braun J.T., Wick M.R., et al. A clinicopathologic and immunohistochemical analysis of 53 cases of medulloblastoma with emphasis on synaptophysin expression. Mod Pathol 1990, 3:164-170.
19. Cogen P.H., MacDonald J.D. Tumor suppressor genes and medulloblastoma. J Neurooncol 1996, 29:103-112.
20. Cohen B.H., Zeltzer P.M., Boyett J.M., et al. Prognostic factors and treatment results for supratentorial primitive neuroectodermal tumors in children using radiation and chemotherapy: a Childrens Cancer Group randomized trial. J Clin Oncol 1995, 13:1687-1696.
21. Dai A.I., Backstrom J.W., Burger P.C., et al. Supratentorial primitive neuroectodermal tumors of infancy: clinical and radiologic findings. Pediatr Neurol 2003, 29:430-434.
22. de Bont J.M., Packer R.J., Michiels E.M., et al. Biological background of pediatric medulloblastoma and ependymoma: a review from a translational research perspective. Neuro-oncol 2008, 10:1040.
23. De Bustos C., Smits A., Stromberg B., et al. A PDGFRA promoter polymorphism, which disrupts the binding of ZNF148, is associated with primitive neuroectodermal tumours and ependymomas. J Med Genet 2005, 42:31-37.
24. de Haas T., Hasselt N., Troost D., et al. Molecular risk stratification of medulloblastoma patients based on immunohistochemical analysis of MYC, LDHB, and CCNB1 expression. Clin Cancer Res 2008, 14:4154.
25. Deutsch M., Thomas P.R.M., Krischer J., et al. Results of a prospective randomized trial comparing standard dose neuroaxis irradiation (3,600cGy/20) with reduced neuroaxis irradiation (2,340/13) in patients with low-stage medulloblastoma: a combined Children's Cancer Group - Pediatric Oncology Group study. Pediatr Neurosurg 1996, 24:167-177.
26. De Vathaire F., Francois P., Hill C., et al. Role of radiotherapy and chemotherapy in the risk of second malignant neoplasms after cancer in childhood. Br J Cancer 1989, 59:792-796.
27. Donahue B. Short- and long-term complications of radiation therapy for pediatric brain tumors. Pediatr Neurosurg 1992, 18:207-217.
28. Duffner P.K., Cohen M.E., Thomas P.R.M., et al. The long-term effects of cranial irradiation on the central nervous system. Cancer 1985, 56:1841-1846.
29. Duffner P.K., Cohen M.E., Voorhees M.L., et al. Long-term effects of cranial irradiation on endocrine function in children with brain tumors: a prospective study. Cancer 1985, 56:2189-2193.
30. Duffner P.K., Horowitz M.E., Krischer J.P., et al. Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors. N Engl J Med 1993, 328:1725-1731.
31. Dunkel I.J., Finlay J. High dose chemotherapy with autologous stem cell rescue for patients with medulloblastoma. J Neurooncol 1996, 29:69-74.
32. Eberhart C.G., Kratz J., Wang Y., et al. Histopathological and molecular prognostic markers in medulloblastoma: c-myc, N-myc, TrkC, and anaplasia. J Neuropathol Exp Neurol 2004, 63:4441-4449.
33. Ellenberg L., McComb J.G., Siegel S., et al. Factors affecting intellectual outcome in pediatric brain tumor patients. Neurosurgery 1987, 21:638-644.
34. Ellison D.W., Onilude O.E., Lindsey J.C., et al. Beta-catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children's Cancer Study Group Brain Tumour Committee. J Clin Oncol 2005, 23:7951-7957.
35. Evans A.E., Jenkin R.D., Sposto R., et al. The Treatment of medulloblastoma. Results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone. Neurosurgery 1990, 72:572-582.
36. Evans D.G.R., Farndon P.A., Burnell L.D., et al. The incidence of Gorlin syndrome in 173 consecutive cases of medulloblastoma. Br J Cancer 1991, 64:959-961.
37. Farwell J., Flannery J.T. Second primaries in children with central nervous system tumors. J Neurooncol 1984, 2:371-375.
38. Farwell J.R., Dohrmann G.J., Glannery J.T. Medulloblastoma in childhood: an epidemiological study. J Neurosurg 1984, 61:657-664.
39. Fernandez-Teijeiro A., Betensky R.A., Sturla L.M., et al. Combining gene expression profiles and clinical parameters for risk stratification in medulloblastomas. J Clin Oncol 2004, 22:994-998.
40. Friedman H.S., Bigner S.H., Bigner D.D. Cyclophosphamide therapy of medulloblastoma: from the laboratory to the clinic and back again (and again and again). J Neurooncol 1995, 24:103-108.
41. Gajjar A., Fouladi M., Walter A.W., et al. Comparison of lumbar and shunt cerebrospinal fluid specimens for cytologic detection of leptomeningeal disease in pediatric patients with brain tumors. J Clin Oncol 1999, 17:1825-1828.
42. Gajjar A., Hernan R., Kocak M., et al. Clinical, histopathologic, and molecular markers of prognosis: toward a new disease risk stratification system for medulloblastoma. J Clin Oncol 2004, 22:984-993.
43. Gajjar A., Chintagumpala M., Ashley D., et al. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. Lancet Oncol 2006, 7:813-820.
44. Gentet J.C., Bouffet E., Doz F., et al. Preirradiation chemotherapy including "eight drugs in one day" regimen and high-dose methotrexate in childhood medulloblastoma: results of the M7 French Cooperative Study. J Neurosurg 1995, 82:608-614.
45. Geyer J.R., Sposto R., Jennings M., et al. Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: a report from the Children's Cancer Group. J Clin Oncol 2005, 23:7621-7631.
46. Giangaspero F., Chieco P., Ceccarelli C., et al. "Desmoplastic" versus "classic" medulloblastoma: comparison of DNA content, histopathology and differentiation. Virchows Arch A Pathol Anat Histopathol 1991, 418:207-214.
47. Giangaspero F., Rigobello L., Badiali M., et al. Large-cell medulloblastomas. A distinct variant with highly aggressive behavior. Am J Surg Pathol 1992, 16:687-693.
48. Giangaspero F., Perilongo G., Fondelli M.P., et al. Medulloblastoma with extensive nodularity: a variant with favorable prognosis. J Neurosurg 1999, 91:971-977.
49. Giangaspero F., Bigner S.H., Kleihues P., et al. Medulloblastoma. Pathology and Genetics of Tumours of the Nervous System 2000, 1:129-137. IARC Press, Lyons. P. Kleihues, W.K. Cavenee (Eds.).
50. Gilbertson R.J., Pearson A.D., Perry R.H., et al. Prognostic significance of the c-erbB-2 oncogene product in childhood medulloblastoma. Br J Cancer 1995, 71:473-477.
51. Gilbertson R., Wickramasinghe C., Hernan R., et al. Clinical and molecular stratification of disease risk in medulloblastoma. Br J Cancer 2001, 85:705-712.
52. Goel A. Whither preoperative shunts for posterior fossa tumors?. Br J Neurosurg 1993, 7:395-399.
53. Gould V.E., Jansson D.S., Molenaar W.M., et al. Primitive neuroectodermal tumors of the central nervous system. Patterns of expression of neuroendocrine markers, and all classes of intermediate filament proteins. Lab Invest 1990, 62:498-509.
54. Gould V.E., Rorke L.B., Jansson D.S., et al. Primitive neuroectodermal tumors of the central nervous system express neuroendocrine markers and may express all classes of intermediate filaments. Hum Pathol 1990, 21:245-252.
55. Grotzer M.A., Janss A.J., Fung K., et al. TrkC expression predicts good clinical outcome in primitive neuroectodermal brain tumors. J Clin Oncol 2000, 18:1027-1035.
56. Grotzer M.A., Hogarty M.D., Janss A.J., et al. MYC messenger RNA expression predicts survival outcome in childhood primitive neuroectodermal tumor/medulloblastoma. Clin Cancer Res 2001, 7:2425-2433.
57. Grotzer M.A., von Hoff K., von Bueren A.O., et al. Which clinical and biological tumor markers proved predictive in the prospective multicenter trial HIT'91 - implications for investigating childhood medulloblastoma. Klin Padiatr 2007, 219:312-317.
58. Gurney J.G., Bunin G.R. CNS and miscellaneous intracranial and intraspinal neoplasms. Cancer Incidence and Survival Among Children and Adolescents: United States SEER Program 1975-1995 1999, 51-63. National Cancer Institute, Bethesda, NIH Pub. No. 99-4649. L.A.G. Ries, C.L. Kosary, B.F. Hankey (Eds.).
59. Gurney J.G., Kadan-Lottick N.S., Packer R.J., et al. Endocrine and cardiovascular late effects among adult survivors of childhood brain tumors: Childhood Cancer Survivor Study. Cancer 2003, 47:663-673.
60. Gurney J., Ness K.K., Stoval M., et al. Final height and body mass index among adult survivors of childhood brain cancer: Childhood Cancer Survivor Study. J Clin Endocrinol Metab 2003, 88:4371-4379.
61. Gururangan S., McLaughlin C., Quinn J., et al. High-dose chemotherapy with autologous stem-cell rescue in children and adults with newly diagnosed pineoblastomas. J Clin Oncol 2003, 21:2187-2191.
62. Hart M.N., Earle K.M. Primitive neuroectodermal tumors of the brain in children. Cancer 1973, 32:890-897.
63. Hawkins M.M., Draper G.J., Kingston J.E. Incidence of second primary tumors among childhood cancer survivors. Br J Cancer 1987, 56:339-347.
64. Heikens J., Michiels E.M.C., Behrendt H., et al. Long-term neuro-endocrine sequelae after treatment for childhood medulloblastoma. Eur J Cancer 1998, 34:1592-1597.
65. Helton K.J., Gajjar A., Hill D.A., et al. Medulloblastoma metastatic to the suprasellar region at diagnosis: a report of six cases with clinicopathologic correlation. Pediatr Neurosurg 2002, 37:111-117.
66. Hoffman H., Hendrick E., Humphreys R. Metastasis via ventriculoperitoneal shunt in patients with medulloblastoma. J Neurosurg 1976, 44:562-566.
67. Huber J.F., Bradley K., Spiegel B.J., et al. Long-term effects of transient cerebellar mutism after cerebellar astrocytoma or medulloblastoma tumor resection in childhood. Childs Nerv Sys 2006, 22:132-138.
68. Inda M.M., Mercapide J., Munoz J., et al. PTEN and DMBT1 homozygous deletion and expression in medulloblastomas and supratentorial primitive neuroectodermal tumors. Oncol Rep 2004, 12:1341-1347.
69. Inda M.M., Perot C., Guillaud-Bataille M., et al. Genetic heterogeneity in supratentorial and infratentorial primitive neuroectodermal tumours of the central nervous system. Histopathology 2005, 47:631-637.
70. Jakacki R. Pineal and nonpineal supratentorial primitive neuroectodermal tumors. Childs Nerv Syst 1999, 15:586-591.
71. Jakacki R., Zeltzer P.M., Boyett J.M., et al. Survival and prognostic factors following radiation and/or chemotherapy for primitive neuroectodermal tumors of the pineal region in infants and children: a report of the Childrens Cancer Group. J Clin Oncol 1995, 13:1377-1383.
72. Jamjoon Z.A., Jamjoon A.B., Sulaiman A.H., et al. Systemic metastasis of medulloblastoma through ventriculoperitoneal shunt; report of a case and critical analysis of the literature. Surg Neurol 1993, 40:403-410.
73. Katsetos C.D., Herman M.M., Frankfurter A., et al. Cerebellar desmoplastic medulloblastomas. A further immunohistochemical characterization of the reticulin-free pale islands. Arch Pathol Lab Med 1989, 113:1019-1029.
74. Khalili K., Del Valle L., Otte J., et al. Human neurotropic polyomavirus, JCV, and its role in carcinogenesis. Oncogene 2003, 22:5181.
75. Kuhl J., Muller H.L., Berthold F., et al. Preradiation chemotherapy of children and young adults with malignant brain tumors: results of the German pilot trial HIT'88/'89. Klin Padiatr 1998, 210:227-233.
76. Lacombe D., Chateil J.F., Fontan D., et al. Medulloblastoma in nevoid basal cell carcinoma syndrome: case reports and review of the literature. Genet Couns 1990, 1:273-277.
77. Lee C.T., Bilton S.D., Famigliette R.M., et al. Treatment planning with protons for pediatric retinoblastoma, medulloblastoma, and pelvic sarcoma: How do protons compare with other conformal techniques?. Int J Radiat Oncol Biol Phys 2005, 63:362-372.
78. Lee M., Wisoff J.H., Abbott R., et al. Management of hydrocephalus in children with medulloblastoma: prognostic factors for shunting. Pediatr Neurosurg 1994, 20:240-247.
79. Leonard J.R., Cai D.X., Rivet D.J., et al. Large cell/anaplastic medulloblastomas and medullomyoblastomas: clinicopathological and genetic features. J Neurosurg 2001, 95:82-88.
80. Liu Y., Mao B., Hokeung N., et al. Expression of C-myc and N-myc protein in adulthood and childhood medulloblastomas and prognostic analysis. Hua Zi Yi Ke Da Xue Xue Bao 2001, 32:120-122.
81. Livesey E.A., Hindmarsh P.C., Brook C.G.D., et al. Endocrine disorders following treatment of childhood brain tumours. Br J Cancer 1990, 61:622-625.
82. MacDonald T.J., Brown K.M., LaFleur B., et al. Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease. Nat Genet 2001, 29:143-152.
83. MacDonald T.J., Rood B., Santi M.R., et al. Advances in the diagnosis, molecular genetics, and treatment of pediatric embryonal CNS tumors. Oncologist 2003, 8:174-186.
84. Marec-Berard B., Jouvet A., Thiesse P., et al. Supratentorial embryonal tumors in children under 5years of age: a SFOP study of treatment with postoperative chemotherapy alone. Med Pediatr Oncol 2002, 38:83-90.
85. Mason W.P., Grovas A., Halpern S., et al. Intensive chemotherapy and bone marrow rescue for young children with newly diagnosed malignant brain tumors. J Clin Oncol 1998, 16:210-221.
86. Massimino M., Gandola L., Spreafico F., et al. Supratentorial primitive neuroectodermal tumors (S-PNET) in children: a prospective experience with adjuvant intensive chemotherapy and hyperfractionated accelerated radiotherapy. Int J Radiat Oncol Biol Phys 2006, 64:1031-1037.
87. McCabe M.G., Jchimura K., Liu L., et al. High-resolution array-based comparative genomic hybridization of medulloblastomas and supratentorial primitive neuroectodermal tumors. J Neuropathol Exp Neurol 2006, 65:549-561.
88. Meyers S.P., Kemp S.S., Tarr R.W. MR imaging features of medulloblastomas. AJR Am J Roentgenol 1992, 158:859-865.
89. Misaki K., Marukawa K., Hayashi Y., et al. Correlation of γ-catenin expression with good prognosis in medulloblastomas. J Neurosurg 2005, 102:197-206.
90. Mulhern R.K., Kepner J.L., Thomas P.R., et al. Neuropsychologic functioning of survivors of childhood medulloblastoma randomized to receive conventional or reduced-dose craniospinal irradiation: a Pediatric Oncology Group study. J Clin Oncol 1998, 16:1723-1728.
91. Neglia J.P., Robison L.L., Stovall M., et al. New primary neoplasms of the central nervous system in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst 2006, 98:1528-1537.
92. Northcott P.A., Korshunov H., Witt A, Witt H., et al. Medulloblastoma comprises four distinct molecular variants. J Clin Oncol 2010, 28:1-12.
93. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Nervous System 2000, Vol. 1. IARC Press, Lyons. P. Kleihues, W.K. Cavenee (Eds.).
94. Packer R.J. Medulloblastoma. J Neurosurg 2005, 103:299-300.
95. Packer R.J., Sutton L.N., Atkins T.E., et al. A prospective study of cognitive function in children receiving whole-brain radiotherapy and chemotherapy: two-year results. J Neurosurg 1989, 70:703-713.
96. Packer R.J., Sutton L.N., Elterman R., et al. Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU, and vincristine chemotherapy. J Neurosurg 1994, 81:690-698.
97. Packer R.J., Cogen P., Vézina G., et al. Medulloblastoma: clinical and biologic aspects. Neuro-oncol 1999, 1:232-250.
98. Packer R.J., Goldwein J., Nicholson H.S., et al. Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: a Children's Cancer Group Study. J Clin Oncol 1999, 17:2127.
99. Packer R.J., Biegel J.A., Blaney S., et al. Atypical teratoid/rhabdoid tumor of the central nervous system: report on workshop. J Pediatr Hematol Oncol 2002, 24:337-342.
100. Packer R.J., Gurney J.G., Punyko J.A., et al. Longterm neurologic and neurosensory sequelae in adult survivors of a childhood brain tumors: Childhood Cancer Survivor Study. J Clin Oncol 2003, 21:3255-3261.
101. Packer R.J., Rood B.R., MacDonald T.J. Medulloblastoma: present concept of stratification into risk groups. Pediatr Neurosurg 2003, 39:60-67.
102. Packer R.J., Gajjar A., Vezina G., et al. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol 2006, 24:4202-4208.
103. Papo I., Caruselli G., Luongo A. External ventricular drainage in the management of posterior fossa tumors in children and adolescents. Neurosurgery 1982, 10:13-15.
104. Pearl G.S., Takei Y. Cerebellar "neuroblastoma": nosology as it relates to medulloblastoma. Cancer 1981, 14:772-779.
105. Perez-Martinez A., Quintero V., Vicent M.G., et al. High-dose chemotherapy with autologous stem cell rescue as first line of treatment in young children with medulloblastoma and supratentorial primitive neuroectodermal tumors. J Neurooncol 2004, 67:101-106.
106. Pfister S., Remke M., Benner A., et al. Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci. J Clin Oncol 2009, 27:1627.
107. Pollack I.F., Polinko P., Albright A.L., et al. Mutism and pseudobulbar symptoms after resection of posterior fossa tumors in children: incidence and pathophysiology. Neurosurgery 1995, 37:885-893.
108. Pollack I.F., Polinko P., Albright A.L., et al. Neurobehavioral syndromes following posterior fossa surgery in children. The Cerebellum and Cognition 1997, 411-432. Academic Press, San Diego. J.D. Schmahmann (Ed.).
109. Pomeroy S., Tamayo P., Gaasenbeek M., et al. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 2002, 415:436-442.
110. Prados M.D., Warnick R.E., Wara W.M., et al. Medulloblastoma in adults. Int J Radiat Oncol Biol Phys 1994, 32:1145-1152.
111. Radcliffe J., Packer R.J., Atkins T.E., et al. Three- and four-year cognitive outcome in children with noncortical brain tumors treated with whole-brain radiotherapy. Ann Neurol 1992, 32:551-554.
112. Raffel C., Jenkins R.B., Frederick L., et al. Sporadic medulloblastomas contain PTCH mutation. Cancer Res 1997, 57:842-845.
113. Ray A., Ho M., Ma J., et al. A clinicobiological model predicting survival in medulloblastoma. Clin Cancer Res 2004, 10:7613-7620.
114. Read T.-A., Hegedus B., Wechsler-Reya R., et al. The neurobiology of neuro-oncology. Ann Neurol 2006, 6:3-11.
115. Reddy A.T., Janss A.J., Phillips P.C., et al. Outcome for children with supratentorial primitive neuroectodermal tumors treated with surgery, radiation, and chemotherapy. Cancer 2000, 88:2189-2193.
116. Ris M.D., Packer R., Goldwein J., et al. Intellectual outcome after reduced-dose radiation therapy plus adjuvant chemotherapy for medulloblastoma: a Children's Cancer Group study. J Clin Oncol 2001, 19:3470-3476.
117. Robertson P.L., Muraszko K.M., Holmes E.J., et al. Incidence and severity of postoperative cerebellar mutism syndrome in children with medulloblastoma: a prospective study by the Children's Oncology Group. J Neurosurg 2006, 105:444-451.
118. Rood B.R., Zhang H., Weitman D.M., et al. Hypermethylation of HIC-1 and 17p allelic loss in medulloblastoma. Cancer Res 2002, 62:3794-3797.
119. Rorke L.B., Hart M.N., McLendon R.E. Supratentorial primitive neuroectodermal tumors (NET). Pathology and Genetics of Tumours of the Nervous System 2000, 1:141-144. IARC Press, Lyons. P. Kleihues, W.K. Cavenee (Eds.).
120. Rushing E.J., Olsen C., Mena H., et al. Central nervous system meningiomas in the first two decades of life: a clinopathological analysis of 87 patients. J Neurosurg 2005, 103:489-495.
121. Rutkowski S., Bode U., Deinlein F., et al. Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. N Engl J Med 2005, 352:978-986.
122. Rutkowski S., von Hoff K., Emser A., et al. Survival and prognostic factors of early childhood medulloblastoma: an international meta-analysis. J Clin Oncol 2010, 28:4961-4968.
123. Segal R.A., Goumnerova L.C., Kwon Y.K., et al. Expression of the neurotrophin receptor TrkC is linked to a favorable outcome in medulloblastoma. Proc Natl Acad Sci U S A 1994, 91:12867-12871.
124. Shalet S.M. Endocrine consequences of treatment of malignant disease. Arch Dis Child 1989, 64:1635-1641.
125. Sheikh B.Y., Kanaan I.N. Medulloblastoma in adults. J Neurosurg Sci 1994, 38:229-234.
126. Shuper A., Packer R.J., Vezina L.F., et al. Complicated migraine-like episodes in children following cranial irradiation and chemotherapy. Neurology 1995, 45:1837-1840.
127. St Clair W.H., Adams J.A., Bues M., et al. Advantage of protons compared to conventional X-ray or IMRT in the treatment of a pediatric patients with medulloblastoma. Int J Radiat Oncol Biol Phys 2004, 58:727-734.
128. Steinbok P., Cochrane D.D., Perrin R., et al. Mutism after posterior fossa tumour resection in children: incomplete recovery on long-term follow-up. Pediatr Neurosurg 2003, 39:179-183.
129. Strickler H.D., Rosenberg P.S., Devesa S.S., et al. Contamination of poliovirus vaccine with SV40 and the incidence of medulloblastoma. Med Pediatr Oncol 1999, 32:77-78.
130. Takei H., Nguyen Y., Mehta V., et al. Low-level copy gain versus amplification of myc oncogenes in medulloblastoma: utility in predicting prognosis and survival. Laboratory investigation. J Neurosurg Pediatr 2009, 3:61.
131. Taylor R.E., Bailey C.C., Robinson K., et al. Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: the International Society of Paediatric Oncology/United Kingdom Children's Cancer Study Group PNETE-3 Study. J Clin Oncol 2003, 21:1582-1591.
132. Thomas P.R., Deutsch M., Kepner J.L., et al. Low-stage medulloblastoma: final analysis of trial comparing standard-dose with reduced-dose neuroaxis irradiation. J Clin Oncol 2000, 1:3004-3011.
133. Thompson M.C., Fuller C., Hogg T.L., et al. Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J Clin Oncol 2006, 24:1924-1931.
134. Timmermann B., Kortmann R.D., Kuhl J., et al. Role of radiotherapy in the treatment of supratentorial primitive neuroectodermal tumors in childhood: results of the prospective German brain tumor trials HIT 88/89 and 91. J Clin Oncol 2002, 20:842-849.
135. Timmermann B., Kortmann R.D., Kuhl J., et al. Role of radiotherapy in supratentorial primitive neuroectodermal tumor in young children: results of the German HIT-SKK87 and HIT-SKK92 trials. J Clin Oncol 2006, 24:1554-1560.
136. Van Calenbergh F., Van De Laar A., Plets C., et al. Transient cerebellar mutism after posterior fossa surgery in children. Neurosurgery 1995, 37:894-898.
137. Vandeinse D., Hornyak J.E. Linguistic and cognitive deficits associated with cerebellar mutism. Pediatr Rehabil 1997, 1:41-44.
138. Zakrzewska M., Rieske P., Debiec-Rychter M., et al. Molecular abnormalities in pediatric embryonal brain tumors - analysis of loss of heterozygosity on chromosomes 1, 5, 9, 10, 11, 16, 17 and 22. Clin Neuropathol 2004, 23:209-217.
139. Zeltzer P.M., Boyett J.M., Finlay J.L., et al. Metastasis stage, adjuvant treatment and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized Phase III study. J Clin Oncol 1999, 17:832-845.
140. Zerback B.J., Gurney J., Oeffinger K., et al. Psychological outcomes in long-term survivors of childhood brain cancer: a report from the Childhood Survivor Study. J Clin Oncol 2004, 22:999-1006.
141. Zimmerman R.A., Haselgrove J.C., Bilaniuk L.T., et al. Diffusion-weighted imaging and fluid attenuated inversion recovery imaging in the evaluation of primitive neuroectodermal tumors. Neuroradiology 2001, 43:927-933.